The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
 
Rohit Jain
Honoraria - Curio Science; DAVA Oncology; FLASCO; MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Sanofi
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation; DAVA Oncology; FLASCO; Sanofi
 
Faustine Ong
No Relationships to Disclose
 
Bishoy Faltas
Honoraria - Axiom Healthcare Strategies, LLC; Axiom Healthcare Strategies, LLC; Digital Science Press; Urotoday
Consulting or Advisory Role - Astrin Biosciences; Astrin Biosciences; BostonGene; BostonGene; Guardant Health; Immunomedics; Immunomedics; Janssen; Janssen; Merck; Natera; QED Therapeutics; QED Therapeutics; Seagen; Seagen
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Patent royalties/Immunomedics; Patent Royalties: Gilead Biosciences
Travel, Accommodations, Expenses - Guardant Health; Guardant Health
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Di Maria Jiang
Honoraria - Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; Bayer; Bayer; Bayer; EMD Serono; Ipsen; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Medunik; Novartis AAA
Consulting or Advisory Role - AstraZeneca/Merck; Bayer; Janssen Oncology; McKesson; Merck; Novartis AAA; Pfizer; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Seagen
Research Funding - Amgen; Astellas Pharma (Inst); Bayer; Pfizer; Tersera
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; EMD Serono; EMD Serono; Pfizer; Pfizer; Pfizer; Pfizer; Roche
 
Jazlyn Heiligh
No Relationships to Disclose
 
Syeda Mahrukh Hussnain Naqvi
No Relationships to Disclose
 
Youngchul Kim
No Relationships to Disclose
 
Lorraine Pelosof
No Relationships to Disclose
 
Yuanquan Yang
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; The whiteoak group; Xencor
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Incyte (Inst); Novartis (Inst); Recordati (Inst); Xencor (Inst)
 
Laura Graham
No Relationships to Disclose
 
Waddah Arafat
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Merck (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Timothy Synold
No Relationships to Disclose
 
Monica Chatwal
Consulting or Advisory Role - Guidepoint Global; IntrinsiQ; Merck
Speakers' Bureau - Merck
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Dendreon; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Dendreon; Sanofi
 
Jus Chadha
Consulting or Advisory Role - Dendreon
Travel, Accommodations, Expenses - Dendreon
 
Guru Sonpavde
Employment - Exact Sciences (I); Myriad Genetics (I)
Honoraria - Grand Rounds in Urology; Ideology Health; Onviv; PeerView; PrecisCa; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Kura Oncology; Loxo/Lilly; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Astellas Pharma; AVEO; Bayer; Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Janssen Oncology; Medscape; Merck; Natera; Pfizer; Research to Practice; Seagen
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Sumitomo Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Merck; Mereo BioPharma; QED Therapeutics